AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17325405 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay‐led self care support group (6‐weekly sessions to teach self care skills)
Number of subjects: 629
Study 17325405 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 629
Study 15038927 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based treatment
Number of subjects: 542
Study 15038927 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive therapies and combination medications
Number of subjects: 542
Study 15038927 — intervention group
Group type: EXPERIMENTAL
Intervention: Service use
Number of subjects: 542
Study 11351771 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro (LP) combined with insulin lispro protamine suspension (NPL)
Number of subjects: 166
Study 11351771 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin (HR) combined with human NPH insulin (NPH)
Number of subjects: 166
Study 9684796 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose TNFR:Fc (10 mg/m2 i.v., n = 6)
Number of subjects: 18
Study 9684796 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose TNFR:Fc (60 mg/m2 i.v., n = 6)
Number of subjects: 18
Study 9684796 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo, n = 6)
Number of subjects: 18
Study 7802318 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro‐medicamentous anesthesia after Kastrubin‐Kordyukov, n = 24
Number of subjects: 88
Study 7802318 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro‐medicamentous anesthesia after Limoges' technique modified by M.I. Kuzin et al., n = 21
Number of subjects: 88
Study 7802318 — intervention group
Group type: COMPARATOR
Intervention: Combined anesthesia based on NLA agents and placebo (simulated transcerebral electropulse exposure), n = 14
Number of subjects: 88
Study 7802318 — intervention group
Group type: COMPARATOR
Intervention: Combined NLA anesthesia (controls), n = 29
Number of subjects: 88
Study 2657207 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorophyllypt (0.25% solution in physiological sodium chloride solution administered by intravenous drip)
Number of subjects: 22
Study 2657207 — intervention group
Group type: COMPARATOR
Intervention: Traditional antibiotic therapy
Number of subjects: 22
Study 2657207 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorophyllypt
Number of subjects: 22
Study 2657207 — intervention group
Group type: COMPARATOR
Intervention: Broad-action antibiotics
Number of subjects: 22
Study 30835495 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia
Number of subjects: 2620
Study 30835495 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime sleepiness
Number of subjects: 2620
Study 30835495 — intervention group
Group type: EXPERIMENTAL
Intervention: Long sleepers
Number of subjects: 2620
Study 29432877 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D and probiotic co-supplementation (50,000 IU vitamin D every 2 weeks plus 8 × 10^9 CFU/g probiotic)
Number of subjects: 60
Study 27473162 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior approach ISB with 15 ml of ropivacaine 1%
Number of subjects: 84
Study 27473162 — intervention group
Group type: COMPARATOR
Intervention: Posterior approach ISB with 15 ml of ropivacaine 1%
Number of subjects: 84
Study 24521425 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir (LPV/r)
Number of subjects: 323
Study 24521425 — intervention group
Group type: COMPARATOR
Intervention: Nevirapine-based ART
Number of subjects: 323
Study 23530767 — intervention group
Group type: EXPERIMENTAL
Intervention: Active probiotic (Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium bifidum and Streptococcus faecium)
Number of subjects: 107
Study 23530767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 20887495 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg daily of pyridoxine
Number of subjects: 56
Study 20887495 — intervention group
Group type: COMPARATOR
Intervention: 200 mg daily of pyridoxine
Number of subjects: 56
Study 18412725 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-cornered flap technique (group A)
Number of subjects: 20
Study 18412725 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal wedge flap technique (group B)
Number of subjects: 20
Study 15702341 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (24-week program, twice per week, consisting of calf-rise and leg-press exercises at 75% of three-repetition maximum)
Number of subjects: 0
Study 12197572 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 64 microg
Number of subjects: 38
Study 12197572 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 256 microg
Number of subjects: 38
Study 12197572 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate 200 microg
Number of subjects: 38
Study 12197572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 10194002 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic stimuli processed from friction sounds picked up by microphones on fingers of nonsensate hands or prostheses.
Number of subjects: 9
Study 7775054 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter patterns
Number of subjects: 74
Study 7775054 — intervention group
Group type: COMPARATOR
Intervention: Non-letter patterns
Number of subjects: 74
Study 7775054 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter stimuli
Number of subjects: 74
Study 7775054 — intervention group
Group type: COMPARATOR
Intervention: Non-letter stimuli
Number of subjects: 74
Study 2107994 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic antibiotics (SA)
Number of subjects: 1688
Study 2107994 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin bone cement (GBC)
Number of subjects: 1688
Study 7306432 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 50 mg
Number of subjects: 16
Study 7306432 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 100 mg
Number of subjects: 16
Study 7306432 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 16
Study 7306432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7306432 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogue scales for size and weight ratings
Number of subjects: 16
Study 7306432 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogue scales expressing attitudes not directly related to mood
Number of subjects: 16
Study 30379634 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure (VRE)
Number of subjects: 108
Study 30379634 — intervention group
Group type: COMPARATOR
Intervention: Traditional Prolonged Exposure Therapy
Number of subjects: 108
Study 28475831 — intervention group
Group type: EXPERIMENTAL
Intervention: Microarray-based immunoassay using the mimotope Clone A2 (peptide sequence VTPNDDTFDPFR)
Number of subjects: 0
Study 28475831 — intervention group
Group type: EXPERIMENTAL
Intervention: Microarray-based immunoassay
Number of subjects: 0
Study 25884155 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib (RE)
Number of subjects: 192
Study 25884155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 23657721 — intervention group
Group type: EXPERIMENTAL
Intervention: VAST
Number of subjects: 32
Study 23657721 — intervention group
Group type: COMPARATOR
Intervention: Control (10-cc syringe)
Number of subjects: 32
Study 22004306 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-session facilitated group cognitive behavioral therapy-based intervention
Number of subjects: 61
Study 22004306 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control
Number of subjects: 61
Study 19681813 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus QD
Number of subjects: 66
Study 19681813 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus BID
Number of subjects: 66
Study 19681813 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus QD and Tacrolimus BID
Number of subjects: 66
Study 17948077 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional clipped-artery harvesting
Number of subjects: 40
Study 17948077 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified nonclipped-artery harvesting
Number of subjects: 40
Study 14687962 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone-maintained smokers
Number of subjects: 36
Study 14687962 — intervention group
Group type: COMPARATOR
Intervention: Control smokers
Number of subjects: 36
Study 14687962 — intervention group
Group type: COMPARATOR
Intervention: Control nonsmokers
Number of subjects: 36
Study 11587113 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (mean duration: 3.5, 4.9, and 6.4 minutes for sessions 1, 2, and 3 respectively)
Number of subjects: 7
Study 11587113 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no distraction)
Number of subjects: 7
Study 10052670 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (400 mcg)
Number of subjects: 0
Study 10052670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7973119 — intervention group
Group type: EXPERIMENTAL
Intervention: Methazolamide treatment
Number of subjects: 6
Study 7973119 — intervention group
Group type: COMPARATOR
Intervention: Fluorescein dye leakage
Number of subjects: 6
Study 3335117 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (24 micrograms/kg)
Number of subjects: 0
Study 3335117 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (40 micrograms/kg)
Number of subjects: 0
Study 3335117 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (10 micrograms/kg)
Number of subjects: 0
Study 29803537 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation followed by surgery and PHDRB (16-24 Gy) in unirradiated patients (n=25)
Number of subjects: 50
Study 29803537 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery and PHDRB alone (32-40 Gy) in previously irradiated patients (n=25)
Number of subjects: 50
Study 28281117 — intervention group
Group type: EXPERIMENTAL
Intervention: Game-enhanced curriculum (intervention)
Number of subjects: 31
Study 28281117 — intervention group
Group type: COMPARATOR
Intervention: Regular curriculum (control)
Number of subjects: 31
Study 26252548 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine supplementation (6 mg/kg)
Number of subjects: 20
Study 26252548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23937064 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of medical words by hospice team members
Number of subjects: 0
Study 23937064 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical words used by caregivers and team members
Number of subjects: 0
Study 23937064 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical words used by team members
Number of subjects: 0
Study 23937064 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers' response to medical word use
Number of subjects: 0
Study 21564160 — intervention group
Group type: EXPERIMENTAL
Intervention: Terutroban 2.5 mg
Number of subjects: 48
Study 21564160 — intervention group
Group type: EXPERIMENTAL
Intervention: Terutroban 5 mg
Number of subjects: 48
Study 21564160 — intervention group
Group type: EXPERIMENTAL
Intervention: Terutroban 10 mg
Number of subjects: 48
Study 21564160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 19232204 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (ENX)
Number of subjects: 191
Study 19232204 — intervention group
Group type: COMPARATOR
Intervention: Non-fractionated Heparin (NFH)
Number of subjects: 191
Study 17348237 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhong tong'an combined with dexamethasone tablets
Number of subjects: 100
Study 17348237 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone tablets alone
Number of subjects: 100
Study 15087602 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban (10 microg/kg bolus followed by 0.15 microg/kg/min)
Number of subjects: 32
Study 15087602 — intervention group
Group type: COMPARATOR
Intervention: Placebo bolus and infusion
Number of subjects: 32
Study 15087602 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 32
Study 10994902 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (30-60 min moderate-intensity running 3-5 times a week for 12-16 weeks)
Number of subjects: 56
Study 10994902 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program
Number of subjects: 56
Study 10994902 — intervention group
Group type: COMPARATOR
Intervention: Control (untrained)
Number of subjects: 56
Study 9172024 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual buprenorphine 0.2 mg
Number of subjects: 342
Study 9172024 — intervention group
Group type: COMPARATOR
Intervention: oral controlled release morphine 10 mg
Number of subjects: 342
Study 9172024 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine (10 ml) wound infiltration
Number of subjects: 342
Study 7712621 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (600 mg daily for 5 days) + Aspirin (150 mg daily)
Number of subjects: 110
Study 7712621 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Aspirin (150 mg daily)
Number of subjects: 110
Study 3438581 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained theophylline administration
Number of subjects: 10
Study 3438581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31846392 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraperitoneal approach
Number of subjects: 98
Study 29537915 — intervention group
Group type: EXPERIMENTAL
Intervention: Four abbreviated exposures on day 1
Number of subjects: 0
Study 29537915 — intervention group
Group type: COMPARATOR
Intervention: One extended split-belt exposure on day 1
Number of subjects: 0
Study 29537915 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for 4 consecutive days before testing on day 5
Number of subjects: 0
Study 26683453 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily positive affect among nonstudents
Number of subjects: 72
Study 26683453 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily negative affect among nonstudents
Number of subjects: 72
Study 26683453 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily negative affect among college students
Number of subjects: 72
Study 26683453 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekend days
Number of subjects: 72
Study 25712758 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical decompression of nerves in the lower extremity (tibial, superficial, deep and common peroneal nerves)
Number of subjects: 42
Study 25712758 — intervention group
Group type: COMPARATOR
Intervention: Control leg (no intervention)
Number of subjects: 42
Study 25712758 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical decompression of nerves in the lower extremity
Number of subjects: 42
Study 23549864 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin/metformin IR 2.5 mg/500 mg FDC tablet
Number of subjects: 24
Study 23549864 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin/metformin IR 2.5 mg/1,000 mg FDC tablet
Number of subjects: 24
Study 23549864 — intervention group
Group type: COMPARATOR
Intervention: Co-administration of saxagliptin 2.5 mg and metformin IR 500 mg
Number of subjects: 24
Study 23549864 — intervention group
Group type: COMPARATOR
Intervention: Co-administration of saxagliptin 2.5 mg and metformin IR 1,000 mg
Number of subjects: 24
Study 20938315 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe home model
Number of subjects: 371
Study 20938315 — intervention group
Group type: COMPARATOR
Intervention: TIPP sheet
Number of subjects: 371
Study 18450604 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted behavioral intervention
Number of subjects: 19
Study 18450604 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 19
Study 19942984 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapeutic Follow-up (PF) for 12 months
Number of subjects: 161
Study 19942984 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PF)
Number of subjects: 161
Study 19942984 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapeutic Follow-up (PF)
Number of subjects: 161
Study 15895316 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentration arginine aspartate (5.7 g arginine and 8.7 g aspartate)
Number of subjects: 30
Study 15895316 — intervention group
Group type: EXPERIMENTAL
Intervention: Low concentration arginine aspartate (2.8 g arginine and 2.2 g aspartate)
Number of subjects: 30
Study 15895316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11552063 — intervention group
Group type: EXPERIMENTAL
Intervention: WBC-reduced RBCs matched for E, C, and Kell
Number of subjects: 130
Study 9778005 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (0.8 +/- 0.4%)
Number of subjects: 120
Study 9778005 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (3.4 +/- 1.1%)
Number of subjects: 120
Study 9778005 — intervention group
Group type: COMPARATOR
Intervention: Normothermic patients
Number of subjects: 120
Study 9778005 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic patients
Number of subjects: 120
Study 7823274 — intervention group
Group type: EXPERIMENTAL
Intervention: CR group (epithelial collar removed, graft sutured under facial flap)
Number of subjects: 30
Study 7823274 — intervention group
Group type: COMPARATOR
Intervention: CTG group (epithelial collar preserved and left exposed)
Number of subjects: 30
Study 3169046 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 6
Study 3169046 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 6
Study 3169046 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 6
Study 3169046 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists (Verapamil and Diltiazem)
Number of subjects: 6
Study 3169046 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalized patients with AF
Number of subjects: 6
Study 3169046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31273171 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus Ramucirumab with prophylactic pegfilgrastim
Number of subjects: 10
Study 31273171 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus Ramucirumab
Number of subjects: 10
Study 28152178 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini Mental State Examination (MMSE) at hospital admission, discharge, and at 3 and 12 months after discharge
Number of subjects: 302
Study 28152178 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed effects modeling
Number of subjects: 302
Study 26795448 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy and supervised exercise (MTEX)
Number of subjects: 15
Study 26795448 — intervention group
Group type: COMPARATOR
Intervention: Advice and home exercise alone (Ad+HEP)
Number of subjects: 15
Study 24041131 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined buprenorphine-naloxone and behavioral treatment
Number of subjects: 22
Study 22858452 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone at a dose of 2 mg/kg/day (first group: 40 attacks)
Number of subjects: 41
Study 22858452 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone at a dose of 0.5 mg/kg/day (second group: 46 attacks)
Number of subjects: 41
Study 22858452 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone at a dose of 0.5 mg/kg/day (second group)
Number of subjects: 41
Study 22858452 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of fever reduction and interval between attacks
Number of subjects: 41
Study 19417228 — intervention group
Group type: COMPARATOR
Intervention: Euhydrated (EUH)
Number of subjects: 8
Study 19417228 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypohydrated1 (HYPO1)
Number of subjects: 8
Study 19417228 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypohydrated2 (HYPO2)
Number of subjects: 8
Study 17377312 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio/video narratives (UMTS based)
Number of subjects: 30
Study 17377312 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio only narrative (portable MP3)
Number of subjects: 30
Study 17377312 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio only narrative (CD at home)
Number of subjects: 30
Study 17377312 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio and video narrative (DVD at home)
Number of subjects: 30
Study 17377312 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 15250767 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine intake
Number of subjects: 14
Study 12003486 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun Oral-B Battery toothbrush (D4)
Number of subjects: 48
Study 12003486 — intervention group
Group type: COMPARATOR
Intervention: ADA manual toothbrush
Number of subjects: 48
Study 9576634 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4+ T-cell subsets in cerebrospinal fluid (CSF) and peripheral blood
Number of subjects: 73
Study 9576634 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4+ T-cell subsets in CSF
Number of subjects: 73
Study 9576634 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8+ T-cell subsets in CSF
Number of subjects: 73
Study 9576634 — intervention group
Group type: COMPARATOR
Intervention: Distribution of activation markers in CSF and peripheral blood
Number of subjects: 73
Study 7872722 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF-beta 1
Number of subjects: 46
Study 7872722 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF-beta 2
Number of subjects: 46
Study 7872722 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between TGF-beta 1 and TGF-beta 2
Number of subjects: 46
Study 3207656 — intervention group
Group type: EXPERIMENTAL
Intervention: Local scleral buckling alone
Number of subjects: 84
Study 3207656 — intervention group
Group type: COMPARATOR
Intervention: Combined local scleral buckling with encirclement
Number of subjects: 84
Study 29530883 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotus
Number of subjects: 912
Study 29530883 — intervention group
Group type: COMPARATOR
Intervention: CoreValve
Number of subjects: 912
Study 29530883 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotus and CoreValve
Number of subjects: 912
Study 27630085 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma IL-6
Number of subjects: 200